drugset
Drugs / Livmoniplimab
last change Jan 2025 re-read 9 days ago

Livmoniplimab

also known as ABBV-151 · ARGX-115 · PR-1762844

Monoclonal antibody

Developed for
hepatocellular carcinoma · non-small cell lung carcinoma · urothelial carcinoma
Investigated by
AbbVie

Trials 6

today NCT06632951 · Ph 2 NCT06487559 · Ph 1 NCT06236438 · Ph 2/3 NCT06109272 · Ph 2/3 NCT05822752 · Ph 2 NCT03821935 · Ph 1
20192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06487559 Sep 2024 → Oct 2027 expected hepatocellular carcinoma AbbVie Recruiting No outcome recorded
Phase 1 NCT03821935 Feb 2019 → Jun 2027 expected — AbbVie Active not recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT06632951 Jan 2025 → Mar 2027 expected urothelial carcinoma AbbVie Active not recruiting No outcome recorded
Phase 2 NCT05822752 Sep 2023 → Nov 2026 expected hepatocellular carcinoma AbbVie Active not recruiting No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT06236438 Apr 2024 → Oct 2031 expected non-small cell lung carcinoma AbbVie Recruiting No outcome recorded
Phase 2/3 NCT06109272 Jan 2024 → Jan 2027 expected hepatocellular carcinoma AbbVie Active not recruiting No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2018-08-21 argenx argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody argenx.com ↗
2016-04-21 AbbVie AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target abbvie.com ↗
2016-04-19 argenx argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target argenx.com ↗
2015-04-22 argenx arGEN-X Announces Publication on Therapeutic Potential of ARGX-115 in Cancer Immunotherapy argenx.com ↗
2015-03-03 argenx arGEN-X Expands Preclinical Pipeline with ARGX-115: A Novel Simple Antibody™ for Cancer Immunotherapy argenx.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Livmoniplimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT06632951 ↗
5

NCT06236438 ↗

NCT03821935 ↗

NCT06487559 ↗

NCT05822752 ↗

NCT06109272 ↗
Known as ABBV-151 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314989 ↗
Known as ARGX-115 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314989 ↗
Known as PR-1762844 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314989 ↗
Action Inhibit “Livmoniplimab is a monoclonal antibody (mAb) that binds the GARP:TGF-ß1 complex to inhibit activation and release of TGF-ß1.” PMID 39534099 ↗ Oct 2024
Modality Monoclonal antibody “Livmoniplimab is a monoclonal antibody (mAb) that binds the GARP:TGF-ß1 complex to inhibit activation and release of TGF-ß1.” PMID 39534099 ↗ Oct 2024
Route Intravenous “Liquid for intravenous infusion.” NCT03821935 ↗